Core Viewpoint - The article emphasizes the importance of talent acquisition in the field of synthetic biology and protein engineering, highlighting the need for skilled professionals to drive innovation and application in the industrial biotechnology sector [4][5]. Talent Demand - The Tianjin Institute of Industrial Biotechnology is inviting talented individuals from both domestic and international backgrounds to join its efforts in advancing the industrial biotechnology industry [4]. - The Multi-Peptide and Protein Engineering Research Center focuses on synthetic biology innovations, aiming to address challenges in resources, environment, health, and bio-manufacturing [4]. Research Center Overview - The center integrates various disciplines such as microbiology, molecular biology, biochemistry, structural biology, protein engineering, bioinformatics, and computational biology to enhance synthetic biology strategies [4]. Researcher Profile - Zhang Yanfei, a researcher and doctoral supervisor, leads the Multi-Peptide and Protein Engineering Research Center, with a strong academic background and extensive research experience in synthetic biology and metabolic engineering [5]. Job Opportunities - Positions available include Assistant Researcher and Special Research Assistant (Postdoctoral), with competitive salaries and additional funding opportunities from local government initiatives [8][10]. - The Tianjin Port Free Trade Zone offers a funding support of 300,000 yuan for outstanding postdoctoral researchers, which can be combined with the institute's salary [8]. Additional Benefits - Postdoctoral researchers who achieve significant results can apply for higher-level positions within the institute and receive competitive compensation and development opportunities [10][15]. - The institute provides various benefits, including social insurance, housing fund contributions, health check-ups, and paid annual leave [13][14]. Application Process - Applicants are required to submit their resumes and complete the application form, with a long-term open application period [12][18].

Summary of Zencore Conference Call Company Overview - **Company**: Zencore - **Event**: Cantor Global Healthcare Conference - **Date**: September 04, 2025 Key Points Current State and Strategy - Zencore is focused on developing drugs for severe diseases using its XmAb Protein Engineering Platform, targeting unmet needs in both oncology and autoimmune diseases [3][4] - The company is advancing into immunology indications, building on its core oncology expertise [2][3] Bispecific T Cell Engager Program - The XmAb819 bispecific T cell engager targets ENPP3, a protein expressed in renal cell carcinoma (RCC) and other solid tumors [6][10] - Initial data from the dose escalation phase is expected to be presented at the AACR NCI EORTC meeting in October 2025 [10][18] - The program aims to provide a differentiated treatment option in a complex therapeutic landscape for RCC, where existing therapies have limitations [13][14] Clinical Landscape for RCC - Current first-line treatments for advanced clear cell RCC include PD-1 inhibitors and VEGF TKIs, with a lack of effective options for patients who progress beyond second-line therapy [13][14] - Belzutafan, a recently approved therapy, has shown a 25% response rate in heavily pretreated patients, indicating a need for more effective treatments [15][16] TL1A Asset Development - Zencore is developing TL1A as a potential best-in-class molecule for inflammatory bowel disease (IBD) and other indications [22][23] - The company is initiating a Phase 2b study in ulcerative colitis, with plans to explore additional indications like Crohn's disease [24][28] - The TL1A program is positioned to capitalize on the limitations of existing therapies, aiming for improved efficacy and patient outcomes [27][28] Bispecific Antibody Approach - Zencore is exploring bispecific antibodies targeting TL1A and IL-23, with potential applications in IBD and other autoimmune diseases [29][30] - The bispecific approach is expected to offer a safer profile and improved dosing flexibility compared to existing therapies [29][34] Future Outlook - Zencore plans to continue leveraging its engineering tools to develop novel drug candidates while focusing on clinical data generation [51][52] - The company is optimistic about the potential of its current pipeline, particularly in the context of unmet medical needs in oncology and autoimmune diseases [18][52] Additional Insights - The company acknowledges the challenges in modeling drug exposure in the gut for IBD therapies, emphasizing the need for high drug exposure to achieve desired clinical outcomes [39][42] - Zencore is committed to exploring the therapeutic potential of B cell depletion in autoimmune diseases, drawing parallels with successful oncology therapies [45][48] Conclusion - Zencore is strategically positioned to advance its innovative therapies in oncology and immunology, with a strong focus on addressing unmet medical needs through its proprietary engineering platform and clinical development programs [51][52]

Core Insights - Corning Pharmaceutical-B (09966.HK) reported a revenue of RMB 319 million for the six months ending June 30, 2025, representing an 84.1% year-on-year increase [1] - The gross profit reached RMB 288 million, marking a 101.9% year-on-year growth [1] - The profit attributable to the company's owners for the period was RMB 21.575 million [1] - Research and development expenses amounted to RMB 253 million, compared to RMB 195 million in the same period last year [1] Group 1: R&D and Product Pipeline - The company has a highly differentiated internal pipeline consisting of ADCs, monoclonal antibodies, and bispecific antibodies at various stages of development, including one product approved by the National Medical Products Administration and several in Phase III or pivotal clinical trials [1] - The depth and breadth of the company's independent R&D and manufacturing capabilities are highlighted by its structural-guided protein engineering capabilities, allowing for the development of various protein constructs, including single-domain antibodies (sdAb) and engineered proteins [2] - The company has proprietary platforms such as the sdAb platform, CRIB platform, glycan-specific conjugation platform, linker-payload platform, subcutaneous high-concentration formulation platform, and glycan-specific conjugation bispecific payload platform [2] Group 2: Manufacturing Capacity - The company is enhancing its manufacturing capabilities by designing and constructing new facilities that comply with the current Good Manufacturing Practice standards of the National Medical Products Administration, European Medicines Agency, and FDA, with an expected total capacity exceeding 40,000 liters [2] - A newly built ADC bulk and formulation production workshop has already commenced operations, adding to the existing production capacity [2]

Core Viewpoint - The article discusses the development of a novel artificial intelligence-based protein engineering computational simulation method called AiCE, which integrates structural and evolutionary constraints to enhance protein evolution and function design without the need for specialized AI model training [4][12]. Group 1: Protein Engineering Overview - Protein engineering involves modifying amino acid sequences to alter protein structure and function, offering significant potential in both basic research and industrial applications, with market size expected to exceed hundreds of billions [2]. - Current strategies in protein engineering, such as rational design and directed evolution, face challenges including high costs and long experimental cycles, limiting their scalability [2]. Group 2: AI in Protein Engineering - The rapid advancement of artificial intelligence has led to its application in life sciences, particularly in simulating mutations and functional modifications of proteins [3]. - Existing AI models struggle with generalizability across various proteins and require substantial computational and experimental resources, necessitating the development of more efficient and universal protein engineering strategies [3]. Group 3: AiCE Method Development - The AiCE method allows for efficient protein evolution simulation and function design without the need for training dedicated AI models, significantly reducing computational costs [4][12]. - AiCE utilizes existing universal inverse folding models to predict amino acid sequences based on given protein structures, enhancing the accuracy of predictions [5][6]. Group 4: Performance and Applications - AiCE single module achieved a 16% prediction accuracy using 60 deep mutational scanning datasets, with a 37% performance improvement over unrestricted methods [6]. - AiCE multi module predicts mutation combinations effectively while maintaining low computational costs, demonstrating comparable predictive capabilities to larger models [7]. Group 5: Experimental Validation - The research team validated AiCE's functionality across eight diverse proteins, including deaminases and nucleases, confirming its simplicity, efficiency, and versatility [9][10]. - The development of new base editors with enhanced precision and activity, such as enABE8e and enDdd1-DdCBE, showcases AiCE's practical applications in precision medicine and molecular breeding [9][10]. Group 6: Significance and Future Directions - The study highlights the importance of developing efficient bioinformatics tools to reduce computational burdens, making AI-driven protein engineering accessible to more researchers [12]. - The advancements presented in this research mark a significant step forward in the field of protein evolution, elevating AI-based approaches to a new level [12].

Core Viewpoint - Company Huaheng Biological has announced a significant investment plan of 320 million yuan to establish an "AI Precision Fermentation and Protein Engineering Shared Demonstration Project" to maintain its industry leadership and meet market demands for high-quality, low-cost products [1] Group 1: Investment and Project Details - The investment will fund the construction of new production facilities, including workshops, finished goods warehouses, and office buildings, with a projected construction period of 36 months [1] - The funding will come from the company's own or self-raised funds, aimed at building an intelligent production system [1] Group 2: Financial Performance - In 2024, the company reported revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, but net profit fell by 57.80% to 190 million yuan [2] - The decline in net profit is primarily attributed to price pressures on valine products, which are at historical lows due to intensified market competition [2] - In Q1 2025, revenue grew by 37.20% to 687 million yuan, but net profit decreased by 40.98% to 51.1 million yuan [2] Group 3: Research and Development - The company has consistently increased its R&D expenditure from 30.12 million yuan in 2020 to 124 million yuan in 2024, totaling 395 million yuan over five years [3] - In 2024, the company achieved significant breakthroughs in major projects, advancing its product diversification strategy with key projects like bio-based succinic acid and 1,3-propanediol [3] - The company added 10 invention patents and 8 utility model patents in 2024, bringing the total to 78 invention patents and 77 utility model patents by the end of 2024 [3]